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The high-risk recipient: the Eighth Annual
American Society of Transplant Surgeons
State-of-the-Art Winter Symposium
Organ transplantation has evolved such that
programs now commonly transplant recipients
with medical risks, which would have been
prohibitive in the recent past. These patients with
substantially greater comorbidities demand metic-
ulous perioperative and post-transplant care.
Each recipient that comes to the transplant center
brings a certain risk profile and must be assessed
as regards the potential risks that the particular
patient brings to the transplant procedure. The
Eighth Annual American Society of Transplant
Surgeons State-of-the-Art Winter Symposium
explored high-risk recipients, emphasizing issues
that might have previously contraindicated trans-
plantation.
Defining the problem
Organ transplantation inherently involves risk.
The patient and family bring risk, but with little
choice when the faced with end-stage organ
failure. The hospital may develop service to
high-risk patients to fulfill an institutional mission
or improve its reputation. The community may
take pride in the accomplishments of its trans-
plant center. The medical team within the insti-
tution also takes risk. Physicians and other
medical professionals may view high-risk patients
differently, even within the same transplant center.
The transplant surgeon is trained to accept and
manage risk in the course of surgical education,
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Abstract: The evolution of organ transplantation has produced results so
successful that many transplant programs commonly see recipients with
medical risks, which in the past, would have prohibited transplantation. The
Eighth Annual American Society of Transplant Surgeons State-of-the-Art
Winter Symposium focused on the high-risk recipient. The assessment of
risk has evolved over time, as transplantation has matured. The acceptance
of risk associated with a given candidate today is often made in consider-
ation of the relative value of the organ to other candidates, the regulatory
environment, and philosophical notions of utility, equity, and fairness. In
addition, transplant programs must balance outcomes, transplant volume,
and the costs of organ transplantation, which are impacted by high-risk
recipients. Discussion focused on various types of high-risk recipients, such
as those with coronary artery disease, morbid obesity, and hepatitis C;
strategies to reduce risk, such as down-staging of hepatocellular carcinoma
and treatment of pulmonary hypertension; the development of alternatives
to transplantation; and the degree to which risk can or should be used to
define candidate selection. These approaches can modify the impact of re-
cipient risk on transplant outcomes and permit transplantation to be ap-
plied successfully to a greater variety of patients.
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transplant training, and devotion to sick patients
through the provision of a life-saving alternative,
organ transplantation.
Yet, transplant surgeons may come to view high-
risk recipients in divergent ways. Practicing in
institutions with strict protocols may lead surgical
groups to select recipients with low to moderate
risk. Others may see accepting high-risk patients a
moral and/or worthy challenge, or they may be
unwittingly compelled to treat high-risk patients by
a disproportionately precarious patient pool.
There are numerous comorbidities and patient
demographics that add to risk. Older recipient age
unavoidably adds to patient risk. As the transplant
community accepts older patients for listing,
advanced atherosclerotic vascular and heart dis-
ease become more prevalent. Within the last
decade, acceptance of patients who are morbidly
obese, who have hepatitis C, or those with malig-
nancies has broadened considerably.
The first systematic efforts at organ transplan-
tation began with kidney replacement in the 1960s.
At that time, dialysis support and other medical
care were rather primitive, and kidneys were
transplanted into very sick, although young
patients. Between 1970 and 1980, the average
patient was still risky compared to today. By the
1980s, transplantation had evolved into a mature
and accepted medical-surgical option. With the
advent of cyclosporine and other immunosuppres-
sive regimens, success became the expected out-
come, and higher risk patients were referred earlier
for transplant. In the 1990s, efficacy was well
established and demand began to far exceed organ
supply. Transplant team members started to see
very high-risk patients routinely. The recipient at
the extremes of age or with multiple comorbidites,
those needing multiple organs, and those requiring
extraordinary care came to define modern trans-
plantation.
As the millennium changed, there has been little
difference in immunosuppression or surgical tech-
nique. However, external constraints upon trans-
plant programs cast risk in a different light. The
current regulatory structure includes sanctioning
bodies that define standards to which all transplant
professionals must adhere. Regulations, however,
may potentially stifle innovation or even supersede
good clinical judgment. Even well-intentioned
regulation of medical care may add risk through
unintended consequences. For example, the OPTN
policy preferentially allocating kidneys to pediatric
recipients was followed by a decrease in pediatric
living donor transplants and the subsequent
decrease in availability of very good kidneys to
other suitable candidates.
Attention to institutional outcomes is a focus of
the current regulatory framework, and transplant
programs must consider that their outcomes are an
important determinant of program certification
and reimbursement. This may be a particular
challenge when decision-making guided by concern
with outcomes may run counter to the interests of
the individual candidate. While the concept of
stewardship of a precious resource may apply to
the high-risk recipient, under many circumstances,
transplant represents the option with the greatest
potential benefit, indeed the lowest risk option for
that candidate, even if that benefit may be less than
for other candidates.
The challenge of balancing outcomes, transplant
numbers, and costs of organ transplantation is
another matter that every program must address.
Routinely transplanting high-risk recipients may
increase transplant volume, but expanding access
to the sickest patients may be the worst of all
circumstances: diminished outcomes at high cost.
Thus, a transplant center team must make choices
that balance saving lives with obtaining results that
are acceptable to external regulators. The tempta-
tion may be to seek lower-risk recipients. This
contrasts starkly with the history of transplant
surgery. Beyond external oversight, with the cur-
rent organ shortage, when is the high-risk candi-
date too high risk?
Types of high-risk recipients
It is useful to contrast our concept of high-risk with
historical precedents. To that end, Dr. John
Roberts from the University of California at San
Francisco (UCSF) described the long tradition of
surgical innovation in transplantation and re-
minded attendees that the first kidney transplants
in 1954 and the first liver transplant in 1963 were
extremely high-risk situations (1). In the past, the
benefit of transplant was high and the competing
use of the organ was low. Today, the competing
use of the organ is high, which leads us to consider
the limits of recipient risk relative to the value of
the organ to others. An example of this is
transplantation for hepatobiliary malignancies
(2). While five-yr survival had been unacceptably
low, the thoughtful development of recipient
selection processes has improved survival to match
the competing value of that organ to other
candidates (3).
Coronary artery disease (CAD) is a risk factor
that may affect recipients of all organs, as discussed
by George Tellides (Yale). CAD is the single best
predictor of mortality in the end-stage renal disease
(ESRD) population, accounting for more than
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50% of deaths. In kidney recipients, death with
graft function is the primary cause of graft loss,
and CAD the major cause of death (4). The
prevalence of CAD in the ESRD population is
approximately 40%, and after kidney transplanta-
tion the incidence of new CAD is nearly 25% by
15 yr. Modifiable risk factors such as hypertension
and hyperlipidemia are worsened by immunosup-
pression. Pre-transplant management of CAD is
centered on control of modifiable risk factors,
screening, and intervention where appropriate. The
indications for revascularization are similar pre-,
post-transplant and in the general population.
Inflammation may link organ dysfunction, allo-
graft rejection and CAD, as markers of inflamma-
tion, particularly IL-12 and cIFN, predict cardiac
death both before and after kidney transplanta-
tion, and rejection episodes predict cardiac death
post-transplant (5).
Another example of high risk is the non-liver
transplant recipient with hepatitis C (HCV). As
explained by Timothy Pruett (University of Vir-
ginia), the risk in these recipients is primarily the
potential effect of immunosuppression on HCV
infection. Post-transplant mortality is increased in
HCV kidney recipients, having greater mortality
from liver disease and sepsis, but less from cardiac
disease (6, 7). However, they still receive a benefit
from kidney transplantation (6). The use of HCV
positive kidneys not only expands the donor pool
but expedites transplantation for HCV+ kidney
recipients. Patient survival is similar for HCV+
recipients of either an HCV+ or HCV) kidney,
although graft survival is worse with an HCV+
donor. Outcomes are worse when a HCV+ organ
is transplanted into a naı̈ve recipient. While 5–7%
of the kidney waiting list is HCV+, only 2.5% of
candidates are willing to accept HCV+ kidneys.
Whether donor transmission of genotypes with
worse prognosis into a recipient with a more
favorable genotype confers a worse outcome is not
presently known.
The risk associated with the HCV+ donor is
different in extra renal transplantation. HCV+
heart recipients have lower patient survival than
HCV) recipients, and for each recipient group
survival is worse with an HCV+ donor. Significant
limitations on existing data include a lack of
accurate serologic, virologic, and other clinical
information. Patients with HCV are not the same,
so generalized recommendations are difficult. Mak-
ing recommendations for HCV+ candidates with
compensated cirrhosis, who are not candidates for
liver–kidney transplant, is difficult because of a
paucity of data. These patients have typically been
denied kidney-alone transplant because of
concerns about perioperative or post-immunosup-
pressive liver failure, although this approach is
being revisited at selected centers.
The changing definition of recipient risk applies
to psychosocial factors as well. Cheryl Jacobs
(University of Minnesota) noted that as many as
50% of transplant recipients are non-adherent to
their immunosuppressive regimen, and up to 36%
of graft losses are related to compliance issues
(8–10). Predictors of non-adherence include reci-
pient demographics, prior non-compliance, tolera-
bility and complexity of treatment regimen, mental
health, social support, substance abuse, and finan-
cial issues. These factors reinforce the importance
of mental health and social support assessments at
the time of transplant evaluation. After transplant,
treatment plans should be as simple and tolerable
as possible, with ongoing monitoring for barriers
to compliance.
Transplant benefit
Dr. Robert Wolfe (Scientific Registry of Trans-
plant Recipients) discussed the concepts of trans-
plant benefit and life years following transplant
(LYFT), a possible component of a modified
kidney transplant allocation system (11). Giving
priority to candidates projected to have greater
LYFT would lead to longer lifetimes overall
among kidney recipients. Components of a poten-
tial kidney allocation score could be a combination
of accumulated dialysis time, a kidney Donor
Profile Index (DPI), LYFT, and sensitization.
Patients would then be allocated organs having a
similar survival potential as might be expected for
the recipient. Such a system would maximize
LYFT, reduce death with graft function, and
permit all candidates the opportunity to receive a
transplant.
These discussions set the stage for the keynote
debate entitled, ‘‘Road to Nowhere: Are There
Candidates That Should Not Be Transplanted?’’
ASTS President Goran Klintmalm (Baylor)
pointed out that there are many more patients
needing transplants than there are suitable organs;
thus, deciding on patients that should not be
transplanted is an unavoidable necessity. Patients
with poor expected long-term survival because of
underlying disease or comorbidities, or even those
in whom survival is expected but at severely limited
capacity should not be considered for transplant.
Mark Stegall (Mayo Clinic) suggested that many
centers are not transplanting patients who would
benefit. Programmatic considerations are increas-
ingly complicating these decisions; centers may
turn down high risk, but suitable, patients to
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protect their outcomes, and high-risk candidates
are too costly and difficult to care for. Many
candidates are not referred because of inadequate
access to health care, lack of insurance, and
variability in both program selection criteria and
geographic access. To address this, he proposed (i)
more detailed methods of predicting candidate
outcomes and assessing programmatic outcomes;
(ii) accurately assessing the benefit of transplant;
and (iii) ranking deceased donor candidates by
comparative benefit. For the latter, it was empha-
sized that any proposed kidney allocation score
will not result in those with lower benefit being
shut out from the opportunity for transplant. The
underlying question is: Is there a compelling reason
to favor utility over equity? which is ultimately a
societal question.
Risk reduction
Depending on the organ system, there may be
opportunities to mitigate risk by specific interven-
tions. The UCSF down-staging protocols for
hepatocellular cancer (HCC) were presented by
Francis Yao. The Milan criteria give priority to
patients with a single lesion £ 5 cm or two to
three lesions, none >3 cm in the absence of
macroscopic vascular invasion or extra hepatic
spread (12). UCSF has championed an effort to
downstage tumors outside Milan criteria so that
patients become candidates for transplantation
(13–15). Response to locoregional therapy is a
prognostic marker for improved post-transplant
outcome (3). Data presented on 61 patients
showed that successful down-staging can be
achieved in the majority of carefully selected
patients with excellent post-transplant outcomes.
Down-staging may select a subgroup of biologi-
cally favorable tumors.
J. Wesley Alexander (Cincinnati) presented a
series of morbidly obese patients with chronic renal
failure (CRF) who underwent gastric bypass sur-
gery (GBP) either before or after transplant. Dr.
Alexander noted that obesity negatively impacts
both access and outcomes in kidney transplanta-
tion (16). The Cincinnati experience included 10
patients who became morbidly obese post-trans-
plant and then had GBP, and another 48 patients
who had GBP and then either were transplanted
(n = 14), became candidates, or had improvement
in native renal function (n = 9). The majority were
open cases with minimal morbidity and mortality:
no leaks, splenic injuries, transfusions, deep wound
infections, or perioperative deaths. All patients had
a sustained decrease in BMI and in comorbid
conditions (diabetes, hypertension, and hypercho-
lesterolemia) at 12 months. The indications for
GBP in renal failure or renal transplant patients,
he suggested, should be the same as for the general
population.
Abbas Aredhali (UCLA) discussed the manage-
ment of heart transplant candidates with pulmo-
nary hypertension (17). Patients with fixed
pulmonary hypertension (pulmonary vascular
resistance [PVR] > 4, transpulmonary gradient
[TPG] > 15) are not considered heart transplant
candidates. While in the past these patients have
been heart–lung transplant candidates, recently
they have undergone chronic pulmonary vasodila-
tor therapy or received left ventricular assist
devices (LVADs) as a bridge to heart transplant.
About half of candidates with ‘‘fixed’’ disease
receiving sildenafil therapy were successfully trans-
planted, and a randomized trial is in progress (18).
A report of 10 patients with heart failure and
pulmonary hypertension were treated with LVADs
with significant reduction in PVR and TPG; five of
these were successfully transplanted (19).
Peter Gruber (Childrens Hospital of Philadel-
phia) discussed another aspect of the management
of high-risk transplant candidates: maximization of
non-transplant options. He demonstrated that in
patients with hypoplastic left heart syndrome
(HLHS), survival following palliative surgery for
HLHS is nearly equivalent to that following
transplantation (20, 21). Although transplant
recipients are generally those in whom palliative
options are not feasible or have failed, the ability to
manage HLHS without transplant allows immedi-
ate treatment and minimizes waiting times and
waitlist mortality for those who do require trans-
plant.
Sunday debates
The first debate focused on the choice of live
donor grafts versus deceased donor grafts in
pediatric kidney transplantation. Albin Gritsch
(UCLA) argued for the continued preferential use
of live donor grafts in children because of their
superior short- and long-term outcomes, immedi-
ate function, and elective timing of procedure.
The superiority of live donor grafts is particularly
true in the youngest recipients under two yr of
age. Fairness to those awaiting a deceased donor
organ was also cited. Ken Andreoni (University
of North Carolina) countered that most pediatric
transplants occur in larger children, age 13 or
older; fewer than 20% of pediatric transplants are
carried out in children less than five yr of age.
The question was posed: If a child had only one
potential live donor, would you use that live
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donor now, or take an excellent deceased donor
graft offer that comes rapidly in the current
pediatric allocation system? Dr. Andreoni argued
that nearly all children are expected to outlive
their first renal transplant, and outcomes for
excellent deceased donor grafts at five yr compare
favorably to living donor organs. The only
realistic chance of obtaining a future pre-emptive
second transplant for todays pediatric recipient,
who is tomorrows adult recipient, is to have a
waiting live donor.
Mark Ghobrial (UCLA) and Alan Langnas
(University of Nebraska) then debated liver
retransplantation for recurrent hepatitis C.
Dr. Ghobrial, arguing the pro side, pointed out
that in the Baylor experience, outcomes for a first
retransplant for primary non-function and all
other causes were equivalent at 10 yr (22). He
stressed that poor outcomes in HCV retransplant
recipients are strongly tied to the use of donors
over age 60 (23). The tendency for patients with
recurrent HCV to be older and have renal dys-
function also leads to increased early death after
retransplantation (24). Four-yr graft survival was
similar for retransplantation in HCV and non-
HCV recipients in both the UNOS database and
the UCLA experience (25). However, these HCV
retransplant recipients have a 31% higher covar-
iate-adjusted mortality risk compared to non-HCV
recipients (26).
Dr. Langnas argued that the real question is
whether we should retransplant anyone, including
hepatitis C recipients, because 1000 people a year
die on the wait list prior to their first opportunity
at liver transplantation. In addition, post-trans-
plant medical treatment is effective in less than one-
third of HCV recipients, with 20–40% of recipients
displaying cirrhosis by five yr. Because we cur-
rently limit transplantation to those patients that
will have an acceptable outcome, and because one-
yr survival is 50–60% after retransplant, should a
first transplant give someone special access to a
second transplant (27, 28)? He also noted that
more patients are being refused retransplantation
today, especially with MELD scores >30, because
of poor outcomes, and that the answer to HCV
recurrence is better medical therapy, not retrans-
plantation.
In the final debate, economists Drs. Mark
Schnitzler and Roger Evans discussed whether
outcomes for transplants should be risk adjusted.
Dr. Schnitzler (St. Louis University) argued that
the OPTN data have significant predictive power
for transplant outcomes, but some variation is
because of other comorbid pre-transplant condi-
tions that are not measured, as well as center
performance and random variation. By using more
stringent measures of comorbidities, such as the
Elixhauser, Charlson, and CCS scales, some of the
previously unmeasured variance in outcome can be
explained (29).
Dr. Evans disclosed some major financial prob-
lems of Medicare and Social Security and
stressed the need for fiscal responsibility in all
health care. He noted that transplantation is
becoming more expensive in the short term and
less cost effective in the long term as we
transplant older and sicker individuals. Trans-
plant patients account for a disproportionally
high share of annual health care expenditures.
The question was raised: For what should we
adjust risk? Risk adjustment could include the
concepts of case-mix, disease severity, comorbid-
ity, clinical factors, socioeconomic status, age,
ethnicity, and disability status. Candidate and
donor selection criteria have been relaxed (risk
increased) in the name of saving more lives
without consideration of the increased cost
involved. Conservative patient and donor selec-
tion assure the cost-effectiveness of transplanta-
tion by improving outcomes and containing costs,
thus responsibly promoting population health. In
summary, Dr. Evans argued for consensus guide-
lines for patient and donor selection to minimize
variation. Given scarce resources, current finan-
cial realities, and competing demands, transplan-
tation could become viewed as an unworthy
public health investment.
Summary
While risk in the organ transplant recipient has
always been inherent in transplant surgery, the
assessment of risk has evolved with changing eras
and environment. The acceptance of risk associ-
ated with a given candidate today is often made in
consideration of the relative value of the organ to
other candidates, the regulatory environment, and
philosophical notions of utility, equity, and fair-
ness. Modifications of the impact of recipient risk
factors on transplant outcomes, through more
precise identification and characterization of risk,
interventions that reduce risk, and the development
of alternative therapies to transplantation, can play
important roles in the overall management of risk
among transplant candidates and recipients.
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